Eli Lilly’s Alzheimer’s drug gets thumbs down from EU regulator
Eli Lilly’s blockbuster Alzheimer’s disease medication, Kisunla, was not approved for use by the European Union’s drug regulator, who said its benefits don’t outweigh the risks of swelling and bleeding in the brain, citing three deaths among people who have been treated with the medicine.
The decision from the European Medicines Agency is a setback for the Eli Lilly’s latest drug, which the FDA approved for use in the US in July. Analysts polled by FactSet expect Lilly to bring in more than $174 million in revenue from Kisunla this year.
Investors were largely unphased, leaving its share price largely flat Friday morning.
Investors were largely unphased, leaving its share price largely flat Friday morning.
